Callisto Pharmaceuticals reports on 2005 clinical and corporate milestones and achievements; company cites progress in anti-cancer drug development and development and expansion of intellectual property.

(From Chemical Business NewsBase - Press Release)

Callisto Pharmaceuticals Inc (Callisto) has reported significant progress on several major fronts in its year-end corporate review of key business achievements for 2005. Cited in the company's report are a number of clinical and corporate milestones, including Callisto's initiation and further development of two different anti-cancer compounds in human clinical trials, and its advancement of a pre-clinical pipeline of additional novel compounds to treat conditions, including serious gastrointestinal inflammation and biological warfare threats to Homeland Security. L-Annamycin Callisto is developing L-Annamycin as a …